The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells

Clinical Cancer Research

Volumn 11, Issue 12, 2005, Pages 4589-4600

  Pei, Xin Yan ^a   Dai, Yun ^a   Rahmani, Mohamed ^a   Li, Weiqun ^a   Dent, Paul ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 7 HYDROXYSTAUROSPORINE; CASPASE; CYCLIN DEPENDENT KINASE 1; DEXAMETHASONE; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN 6; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P70; SOMATOMEDIN C; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; WESTERN BLOTTING;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CYTOCHROMES C; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FARNESYLTRANSTRANSFERASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; METHIONINE; MULTIPLE MYELOMA; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; STAT3 TRANSCRIPTION FACTOR; STAUROSPORINE; TRANS-ACTIVATORS;

EID: 20444472356     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2346     Document Type: Article

References (64)

1. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2001;1:157-77.
2. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003;102:69-77.
3. Richardson PG, Barlogie B, Berenson J, et al. Phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
4. Adjei AA. Farnesyltransferase inhibitors. Cancer Chemother Biol Response Modif 2003;21:127-44.
5. Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N- and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001;18:212-24.
6. Le Gouili S, Pellat-Deceunynck C, Harousseau JL, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002; 16:1664-7.
7. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004;103:3271-7.
8. Sepp-Lorenzino L, Tjaden G, Moasser MM, et al. Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate Cancer Prostatic Dis 2001;4:33-43.
9. Zhang FL, Kirschmeier P, Carr D, et al. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 1997;272:10232-9.
10. Li T, Sparano JA. Inhibiting Ras signaling in the therapy of breast cancer. Clin Breast Cancer 2003; 6:405-16.
11. Bolick SC, Landowski TH, Boulware D, et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 2003;17:451-7.
12. Shi Y, Gera J, Hsu JH, Van Ness B, Lichtenstein A. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells. Mol Cancer Ther 2003;2:563-72.
13. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991;51:4888-92.
14. 1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene 1999; 41:5691-702.
15. Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600-5.
16. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002;21:1727-38.
17. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 1995;6:927-36.
18. 2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-7.
19. 1-phase accumulation. Jpn J Cancer Res 1999;90:1364-72.
20. Sausville EA. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies. Curr Med Chem Anti-Canc Agents 2003;3:47-56.
21. Harvey S, Decker R, Dai Y, et al. Interactions between 2-fluoroadenine 9-β-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. Clin Cancer Res 2001;7:320-30.
22. Dai Y, Yu C, Singh V, et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 2001; 61:5106-15.
23. Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002;100:3333-43.
24. Jia W, Yu C, Rahmani M, et al. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 2003;102:1824-32.
25. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
26. Dai Y, Rahmani M, Pei XY, et al. Farnesyltransferase inhibitors interact synergistically with the CHK1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both AKT and MEK/ERK pathways and activation of SEK1/JNK. Blood 2005; 105:1706-16.
27. Ochiai N, Uchida R, Fuchida S, et al. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 2003; 102:3349-53.
28. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67.
29. Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST. A mechanism of resistance to glucocorticoids in multiple myeloma: Transient expression of a truncated glucocorticoid receptor mRNA. Blood 1992;79:213-22.
30. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991;51:995-1002.
31. Duan H, Orth K, Chinnaiyan AM, et al. ICE-LAP6, a novel member of the /CE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem 1996;271:16720-4.
32. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;99:239.
33. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-8.
34. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995;1:792-7.
35. Goerner M, Roecklein B, Torok-Storb B, Heimfeld S, Kiem HP. Expansion and transduction of nonenriched human cord blood cells using HS-5 conditioned medium and FLT3-L. J Hematother Stem Cell Res 2000; 9:759-65.
36. Dai Y, Pei XY, Rahmani M, et al. Interruption of the NF-B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 2004;103:2761-70.
37. Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003; 10:2036-45.
38. Li W, Hyun T, Heller M, et al. Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth. Cancer Res 2000;60:3909-15.
39. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
40. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
41. Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989;74:11-3.
42. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000;111:626-34.
43. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-82.
44. Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 1995;85:997-1005.
45. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
46. Chatterjee M, Stuehmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004;104:3712-21.
47. Mizukami Y, Ura H, Obara T, et al. Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells. Biochem Biophys Res Commun 2001;288:198-204.
48. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19:6613-26.
49. Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 1995;55:228-31.
50. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol 2004;31:28-39.
51. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998;95:1369-74.
52. Hoover RR, Mahon FX, Melo JV, Daley GQ. OvercomingSTI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002;100:1068-71.
53. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
54. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000;56:6584-93.
55. Baum C, Kirschmeier P. Predinical and clinical evaluation of farnesyltransferase inhibitors. Curr Oncol Rep 2003;5:99-107.
56. Cox AD. Farnesyltransferase inhibitors: potential role in the treatment of cancer. Drugs 2001;61:723-32.
57. 2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J Biol Chem 1998;273:33455-64.
58. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
59. 1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A 2001;98:9092-7.
60. Ogawa M, Nishiura T, Oritani K, et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 2000;60:4262-9.
61. Rawat R, Rainey GJ, Thompson CD, et al. Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. Blood 2000; 96:3514-21.
62. Hsu JH, Shi Y, Frost P, et al. Lichtenstein A. Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene 2004;23:3368-75.
63. Bhonde MR, Hanski ML, Magrini R, et al. The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein. Oncogene 2005;24:148-56.
64. Cortes J. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma 2003;4 Suppl 1:530-5.